share_log

8-K/A: Current report (Amendment)

8-K/A: Current report (Amendment)

8-K/A:重大事件(修正)
美股SEC公告 ·  2024/06/27 13:44

Moomoo AI 已提取核心信息

Illumina announced it will recognize significant impairment charges in the second quarter of 2024 following an impairment test of GRAIL-related assets. The company estimates a goodwill impairment charge of $1,466 million, representing the full remaining carrying value of GRAIL's goodwill as of March 31, 2024.Additionally, Illumina will record a $420 million impairment charge for GRAIL's in-process research and development (IPR&D) intangible asset. The company stated these charges will be excluded from non-GAAP financial metrics and are not expected to result in any material future cash expenditures.
Illumina announced it will recognize significant impairment charges in the second quarter of 2024 following an impairment test of GRAIL-related assets. The company estimates a goodwill impairment charge of $1,466 million, representing the full remaining carrying value of GRAIL's goodwill as of March 31, 2024.Additionally, Illumina will record a $420 million impairment charge for GRAIL's in-process research and development (IPR&D) intangible asset. The company stated these charges will be excluded from non-GAAP financial metrics and are not expected to result in any material future cash expenditures.
总部位于加利福尼亚州圣迭戈的生物技术公司illumina于2024年6月27日向美国证券交易委员会提交了一份修订后的8-K/ A表。该报告提供了关于先前宣布的某些业务活动分拆的财务影响的更新。Illumina已经完成了减值测试并估计在2024年第二季度将会有一笔146.6亿美元的商誉减值费用,这代表了其GRAIL业务截至2024年3月31日所有尚存的商誉减值。此外,该公司预计会有4.2亿美元的IPR&D无形资产减值损失。这些费用不会导致任何重大的未来现金支出,而且将被排除在Illumina的非GAAP财务指标之外。
总部位于加利福尼亚州圣迭戈的生物技术公司illumina于2024年6月27日向美国证券交易委员会提交了一份修订后的8-K/ A表。该报告提供了关于先前宣布的某些业务活动分拆的财务影响的更新。Illumina已经完成了减值测试并估计在2024年第二季度将会有一笔146.6亿美元的商誉减值费用,这代表了其GRAIL业务截至2024年3月31日所有尚存的商誉减值。此外,该公司预计会有4.2亿美元的IPR&D无形资产减值损失。这些费用不会导致任何重大的未来现金支出,而且将被排除在Illumina的非GAAP财务指标之外。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息